Progressive Supranuclear Palsy Market Expected to Gain Momentum Through 2034, According to DelveInsight

DelveInsight's "Progressive Supranuclear Palsy Market Insights, Epidemiology, and Market Forecast-2034′′ report offers an in-depth understanding of the Progressive Supranuclear Palsy, historical and forecasted epidemiology as well as the Progressive Supranuclear Palsy market trends in the United States, EU4 (Germany, Spain, Italy, France) the United Kingdom and Japan.

The latest healthcare forecast report provides an in-depth analysis of Progressive Supranuclear Palsy, offering comprehensive insights into the Progressive Supranuclear Palsy revenue trends, prevalence, and treatment landscape. The report delves into key Progressive Supranuclear Palsy statistics, highlighting the current and projected market size, while examining the efficacy and development of emerging Progressive Supranuclear Palsy therapies. Additionally, we cover the landscape of Progressive Supranuclear Palsy clinical trials, providing an overview of ongoing and upcoming studies that are poised to shape the future of Progressive Supranuclear Palsy treatment. This report is an essential resource for understanding the market dynamics and the evolving therapeutic options within the Progressive Supranuclear Palsy space.

To Know in detail about the Progressive Supranuclear Palsy market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; Progressive Supranuclear Palsy Market Forecast
https://www.delveinsight.com/sample-request/progressive-supranuclear-palsy-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr

Some of the key facts of the Progressive Supranuclear Palsy Market Report:
• The Progressive Supranuclear Palsy market size was valued ~USD 8.3 million in 2022 and is anticipated to grow with a significant CAGR during the study period (2020-2034).
• In June 2025, Ferrer revealed that the US FDA has awarded Fast Track designation to its investigational therapy FNP-223 for the treatment of progressive supranuclear palsy (PSP).
• In April 2025, AlzProtect's AZP2006 has been selected as one of the first two therapies to be evaluated in the newly initiated national Phase II Platform Trial for Progressive Supranuclear Palsy (PSP) in the US. Supported by the National Institute on Aging (NIH), the trial is designed to accelerate the advancement of effective PSP treatments.
• In October 2024, GemVax & KAEL Co., Ltd. shared that the topline findings from a Phase IIa clinical trial of GV1001, an experimental peptide therapy for progressive supranuclear palsy (PSP), were presented at "Neuro2024: The PSP International Research Symposium" held in Toronto, Canada.
• In September 2024, Ferrer Internacional announced that the first participant has been dosed in the Phase II PROSPER trial, which aims to assess the safety and efficacy of FNP-223, a novel therapy designed to slow the progression of Progressive Supranuclear Palsy.
• In 2024, the United States recorded the largest share of diagnosed prevalent cases of PSP among the 7MM.
• Richardson's syndrome represented over 50% of all phenotype-specific PSP cases in 2024.
• Analysis indicates that PSP was more common in males than females in 2024, with around 60% of cases found in men.
• In Japan, nervous system disorders were the most frequently reported comorbidities associated with PSP in 2024.
• At present, no FDA-approved treatments are available for progressive supranuclear palsy (PSP). Nonetheless, medications such as levodopa, amantadine, ropinirole, hypnotics, anxiolytics, botulinum toxin, and others are used to help control symptoms.
• The PSP pipeline is expanding, with investigational therapies including AZP2006 (AlzProtect), AMX0035 (Amylyx Pharmaceuticals), TPN-101 (Transposon Therapeutics), FNP-223 (Ferrer), among others.
• Key Progressive Supranuclear Palsy Companies: Woolsey Pharmaceutical, Asahi Kasei Pharma, AlzProtect, Amylyx Pharmaceuticals, Transposon Therapeutics, Oncolys Biopharma's, Ferrer/Asceneuron, GemVax & Kael, Ferrer Internacional S.A., Allon Therapeutics, Amylyx Pharmaceuticals, EmeraMed, and others
• Key Progressive Supranuclear Palsy Therapies: BRAVYL (fasudil), AZP2006 (ezeprogind), AMX0035, TPN-101/OBP-601 (censavudine), ASN90, GV1001, FNP-223, Davunetide, AMX0035, NBMI, and others
• The Progressive Supranuclear Palsy market is expected to surge due to the disease's increasing prevalence and awareness during the forecast period. Furthermore, launching various multiple-stage Progressive Supranuclear Palsy pipeline products will significantly revolutionize the Progressive Supranuclear Palsy market dynamics.
• In 2022, the total number of prevalent Progressive Supranuclear Palsy (PSP) cases was estimated to be around 80,706 across the 7MM.
• In 2022, Japan had the highest prevalence of Progressive Supranuclear Palsy (PSP), contributing almost 29%, while Spain had the lowest, accounting for about 7% of the total prevalent cases.
• According to DelveInsight analysis, in 2022, the United States had the highest number of diagnosed prevalent cases, representing approximately 33% of the total cases across the 7MM countries.
• Among the EU4 and the UK, Germany reported the highest number of diagnosed prevalent cases of PSP, with approximately 1,646 cases, while Spain had the lowest, with around 941 cases in 2022.
• In 2022, approximately 3,077 males and 2,674 females in the US were diagnosed with PSP.

Progressive Supranuclear Palsy Overview
Progressive supranuclear palsy (PSP) is a rare, degenerative neurological disorder that affects movement, balance, vision, speech, and swallowing. It is caused by the deterioration of cells in the brain, particularly in areas that control these functions, such as the brainstem and basal ganglia. Symptoms of PSP typically include difficulty with balance and walking, eye movement problems (especially looking up or down), stiffness, and slurred speech. PSP progresses over time, and there is currently no cure, though treatment can help manage symptoms. It is often misdiagnosed as Parkinson's disease due to overlapping symptoms.

Get a Free sample for the Progressive Supranuclear Palsy Market Forecast, Size & Share Analysis Report:
https://www.delveinsight.com/report-store/progressive-supranuclear-palsy-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr

Progressive Supranuclear Palsy Epidemiology
The epidemiology section provides insights into the historical, current, and forecasted epidemiology trends in the seven major countries (7MM) from 2020 to 2034. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. The epidemiology section also provides a detailed analysis of the diagnosed patient pool and future trends.

Progressive Supranuclear Palsy Epidemiology Segmentation:
The Progressive Supranuclear Palsy market report proffers epidemiological analysis for the study period 2020-2034 in the 7MM segmented into:
• Total Prevalent Cases of PSP in the 7MM
• Total Diagnosed Prevalent Cases of PSP in the 7MM
• Gender-specific Diagnosed Prevalent Cases of PSP in the 7MM
• Phenotype-specific Diagnosed Prevalent Cases of PSP in the 7MM
• Comorbidity Associated Cases with PSP in the 7MM

Download the report to understand which factors are driving Progressive Supranuclear Palsy epidemiology trends @ Progressive Supranuclear Palsy Epidemiology Forecast
https://www.delveinsight.com/sample-request/progressive-supranuclear-palsy-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr

Progressive Supranuclear Palsy Drugs Uptake and Pipeline Development Activities
The drugs uptake section focuses on the rate of uptake of the potential drugs recently launched in the Progressive Supranuclear Palsy market or expected to get launched during the study period. The analysis covers Progressive Supranuclear Palsy market uptake by drugs, patient uptake by therapies, and sales of each drug.
Moreover, the therapeutics assessment section helps understand the drugs with the most rapid uptake and the reasons behind the maximal use of the drugs. Additionally, it compares the drugs based on market share.
The report also covers the Progressive Supranuclear Palsy Pipeline Development Activities. It provides valuable insights about different therapeutic candidates in various stages and the key companies involved in developing targeted therapeutics. It also analyzes recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.

Progressive Supranuclear Palsy Therapies and Key Companies
• BRAVYL (fasudil): Woolsey Pharmaceutical/Asahi Kasei Pharma
• AZP2006 (ezeprogind): AlzProtect
• AMX0035: Amylyx Pharmaceuticals
• TPN-101/OBP-601 (censavudine): Transposon Therapeutics/Oncolys Biopharma's
• ASN90: Ferrer/Asceneuron
• GV1001: GemVax & Kael
• FNP-223: Ferrer Internacional S.A.
• Davunetide: Allon Therapeutics
• AMX0035: Amylyx Pharmaceuticals
• NBMI: EmeraMed

Discover more about therapies set to grab major Progressive Supranuclear Palsy market share @ Progressive Supranuclear Palsy Treatment Landscape
https://www.delveinsight.com/sample-request/progressive-supranuclear-palsy-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr

Progressive Supranuclear Palsy Market Strengths
• The new MDS diagnostic criteria for PSP expands the clinical spectrum of the disease by incorporating conditions suggestive of PSP and a variety of symptomatic PSP phenotypes.
• Advocacy and support organizations are dedicated to raising awareness, providing resources, and supporting PSP-affected individuals and families.
• Improvement in understanding PSP pathogenesis has led to the discovery of potential therapies that target tau protein through various modes of actions

Progressive Supranuclear Palsy Market Opportunities
• The lack of approved therapies provides lucrative opportunities for pharma players to develop disease-modifying therapies and capitalize on the untapped market
• Increasing research can lead to a deeper understanding of PSP, including its underlying mechanisms, risk factors, and potential therapeutic targets
• Research focusing on the identification of better imaging and biofluid biomarkers will promote early and accurate diagnosis enrollment of appropriate patients who are likely to show more clear beneficial effects in clinical trials

Scope of the Progressive Supranuclear Palsy Market Report
• Study Period: 2020-2034
• Coverage: 7MM [The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan]
• Key Progressive Supranuclear Palsy Companies: Woolsey Pharmaceutical, Asahi Kasei Pharma, AlzProtect, Amylyx Pharmaceuticals, Transposon Therapeutics, Oncolys Biopharma's, Ferrer/Asceneuron, GemVax & Kael, Ferrer Internacional S.A., Allon Therapeutics, Amylyx Pharmaceuticals, EmeraMed, and others
• Key Progressive Supranuclear Palsy Therapies: BRAVYL (fasudil), AZP2006 (ezeprogind), AMX0035, TPN-101/OBP-601 (censavudine), ASN90, GV1001, FNP-223, Davunetide, AMX0035, NBMI, and others
• Progressive Supranuclear Palsy Therapeutic Assessment: Progressive Supranuclear Palsy current marketed and Progressive Supranuclear Palsy emerging therapies
• Progressive Supranuclear Palsy Market Dynamics: Progressive Supranuclear Palsy market drivers and Progressive Supranuclear Palsy market barriers
• Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter's five forces, BCG Matrix, Market entry strategies
• Progressive Supranuclear Palsy Unmet Needs, KOL's views, Analyst's views, Progressive Supranuclear Palsy Market Access and Reimbursement

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Gaurav Bora
Email: info@delveinsight.com
Contact No.: +14699457679
City: 304 S. Jones Blvd #2432, Las Vegas
State: Nevada (89107)
Country: United States
Website: https://www.delveinsight.com/consulting

About DelveInsight
DelveInsight is a leading Healthcare Business Consultant, and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.
It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate the business growth and overcome challenges with a practical approach.

This release was published on openPR.